Abstract
Murine monoclonal antibodies (Mab) generated against human tumor antigens (Koprowski and Steplewski 1982) have renewed scientific and clinical interest in passive immunotherapy of human cancer (Kennett et aL 1980). Treatment of B cell leukemias with Mab, for instance, results in immediate reduction of leukemic cells in circulation (Levy and Miller 1983; Ritz et al. 1981). A Mab (17–1A) against an antigen of gastrointestinal cancers (Herlyn et al. 1979) was found to suppress the growth of human tumors in nude mice (Herlyn et al. 1980) and produced significant improvement in the clinical status of a number of patients with metastatic disease (Koprowski 1984a; Sears etal. 1984). As expected, most patients injected with this Mab produced antibody against the murine immunoglobulin (Ig) but, more germaine to this forum, a significant proportion of this antibody was directed against the antigen binding or idiotypic (Id) portion of the molecule (anti-Id) (Koprowski et al. 1984).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
